Biora Therapeutics, Inc. has scheduled its 2024 Annual Meeting of Stockholders for June 5, 2024, to be conducted virtually via live audio webcast. The meeting will address several key proposals, including the election of six director nominees to serve until the 2025 Annual Meeting, the ratification of KPMG LLP as the independent auditor for the year ending December 31, 2024, and the approval of an amendment to increase the number of authorized shares of common stock from 164,000,000 to 300,000,000. Additionally, the meeting will authorize the issuance of shares underlying certain warrants issued pursuant to a Securities Purchase Agreement dated March 31, 2024, and Warrant Amendment Agreements of the same date, in compliance with Nasdaq Listing Rule 5635(d). The Board of Directors has fixed April 16, 2024, as the record date for stockholder eligibility to vote. Stockholders must register by June 4, 2024, to attend the virtual meeting.

Biora Therapeutics, Inc. has scheduled its 2024 Annual Meeting of Stockholders for June 5, 2024, to be conducted virtually via live audio webcast. The meeting will address several key proposals, including the election of six director nominees to serve until the 2025 Annual Meeting, the ratification of KPMG LLP as the independent auditor for the year ending December 31, 2024, and the approval of an amendment to increase the number of authorized shares of common stock from 164,000,000 to 300,000,000. Additionally, the meeting will authorize the issuance of shares underlying certain warrants issued pursuant to a Securities Purchase Agreement dated March 31, 2024, and Warrant Amendment Agreements of the same date, in compliance with Nasdaq Listing Rule 5635(d). The Board of Directors has fixed April 16, 2024, as the record date for stockholder eligibility to vote. Stockholders must register by June 4, 2024, to attend the virtual meeting.